Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tethys tethers Lipomics

This article was originally published in The Gray Sheet

Executive Summary

Diagnostics start-up Tethys Bioscience acquires Lipomics Technologies Sept. 17 for an undisclosed sum to shore up its technology know-how to create new tests beyond its first diabetes risk assessment tool, launched earlier this year. Tethys' PreDx test, which measures levels of several proteins in a patient's blood to calculate a score identifying their risk for developing diabetes, relies on the firm's expertise with protein biomarkers. Lipomics, on the other hand, specializes in profiling lipids, which can be evaluated in combination with proteins as an effective risk assessment tool for chronic conditions, Tethys says. Lipomics' current business centers on contracting to perform biomarker research for drug company development projects, partnerships that could be helpful to Tethys' plan to establish drug-diagnostic co-marketing agreements (1"The Gray Sheet" July 28, 2008, p. 16)

You may also be interested in...



Tethys Builds A Case For Pre-Diabetes Algorithm-Based Screening

Diagnostics start-up Tethys Bioscience is laying the groundwork for its first product - a lab test it says will improve screening of the more than 50 million people at near-term risk for developing type-2 diabetes and help identify the best candidates for early-stage intervention

Biogen And Sage On Plans To Build A Brain Franchise Together

The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.

US FDA Allows Dry-Heat Systems For Mask Deep Cleaning

The guidance document allows manufacturers to promote their dry-heat systems for mask bioburden reduction if they meet certain standards.

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel